AML survival isn’t one number: age, disease risk, and treatment pathway can shift outcomes dramatically. Compare 15–39-year SEER 5-year survival (47.3%) with shorter expectations in older and adverse-risk groups. This page connects survival patterns to factors such as complete remission, post-allogeneic HSCT outcomes, and key genetic subtypes like NPM1 and FLT3-ITD.
Key Takeaways
- The 5-year survival rate for AML patients aged 15-39 years is 47.3% per SEER data 2015-2019
- 5-year OS for AML patients 40-64 years is 28.1%
- Median OS for AML patients over 75 years is 3.5 months with HMA
- 5-year OS for NPM1-mutated AML without FLT3-ITD is 62.5%
- Median OS for FLT3-ITD high allelic ratio AML is 7.4 months
- 3-year OS for IDH1-mutant AML with ivosidenib is 48.2%
- The 5-year overall survival rate for all AML patients aged 0-14 years diagnosed between 2015-2019 is 68.2%
- The 5-year relative survival rate for AML patients overall in the US from 2014-2020 is 29.7%
- Median overall survival for newly diagnosed AML patients in a 2020 meta-analysis is 12.5 months
- 5-year survival rate for favorable-risk AML is 65.2% at 5 years
- 5-year OS for intermediate-risk AML is 38.7%
- Median OS for adverse-risk AML is 8.9 months
- The 5-year survival with intensive chemotherapy alone is 40.2% for fit patients
- Median OS with azacitidine monotherapy in unfit elderly is 10.4 months
- 2-year OS post-allogeneic HSCT in first CR is 62.7%
Overall survival varies widely in AML, from 68.2% in children to just 3.5 months in older adults.
Related reading
01 · Category
Age Specific Survival30 stats
01
The 5-year survival rate for AML patients aged 15-39 years is 47.3% per SEER data 2015-2019
02
5-year OS for AML patients 40-64 years is 28.1%
03
Median OS for AML patients over 75 years is 3.5 months with HMA
04
2-year survival for pediatric AML (0-18) is 65.8% in COG trials
05
5-year OS for AML 65-74 years is 11.2%
06
1-year OS for AML under 20 years is 78.5%
07
Median OS for AML 60-69 years with intensive chemo is 13.8 months
08
3-year OS for young adults 18-39 is 52.4%
09
5-year survival for AML 20-34 years in UK is 45.2%
10
OS at 2 years for octogenarians with AML is 8.1%
11
Pediatric AML 5-year EFS is 52% in recent trials
12
Median survival for AML 70+ years untreated is 1.9 months
13
1-year OS for AML 50-59 years is 55.3%
14
5-year OS for AML adolescents 15-19 is 62.1%
15
2-year survival for elderly 75+ with low-intensity therapy is 22.4%
16
Median OS for AML infants <1 year is 45.6 months
17
3-year OS for adults 30-49 years is 42.7%
18
5-year survival for AML 65+ is 6.8%
19
1-year OS for AML 35-44 years is 68.2%
20
Median OS for very elderly 80+ is 2.8 months with ven/aza
21
2-year OS for young children 1-4 years AML is 75.3%
22
5-year OS for middle-aged 45-64 is 25.9%
23
3-year survival for seniors 70-79 is 15.6%
24
1-year OS for teens 15-19 AML is 70.4%
25
11.2% 5-year OS for AML patients aged 65-74 years
26
6.8% 5-year survival for AML 65+
27
15.6% 3-year OS for seniors 70-79 years
28
75.3% 2-year OS for young children 1-4 years AML
29
22.4% 2-year survival for elderly 75+ with low-intensity therapy
30
65.8% 2-year survival for pediatric AML (0-18) in COG trials
Interpretation
Age Specific Survival Interpretation
From the age-specific survival data, AML outcomes decline sharply with age, dropping from a 47.3% 5-year survival rate for patients aged 15 to 39 to just 11.2% for those aged 65 to 74 and an OS of only 3.5 months for patients over 75.
report visual · Comparison
Age-specific 5-year AML survival is lowest in older adults
Across age groups, 5-year OS for AML is lowest among the oldest patients (age 65+ at 6.8%), while younger patients show substantially higher survival (e.g., age 65–74 at 11.2% and
15.6% 3-year OS for seniors 70-79 years15.6%
11.2% 5-year OS for AML patients aged 65-74 years
11.2%
6.8% 5-year survival for AML 65+
6.8%
source-verifiedseer.cancer.gov2015
02 · Category
Molecular/genetic Survival27 stats
01
5-year OS for NPM1-mutated AML without FLT3-ITD is 62.5%
02
Median OS for FLT3-ITD high allelic ratio AML is 7.4 months
03
3-year OS for IDH1-mutant AML with ivosidenib is 48.2%
04
5-year survival for CEBPA biallelic mutated AML is 55.1%
05
OS for TP53-mutated AML is median 5.2 months regardless of therapy
06
2-year OS for RUNX1-mutated AML is 32.7%
07
5-year RFS for NPM1 mut low FLT3 is 70.3%
08
Median survival for ASXL1-mutated AML is 9.1 months
09
1-year OS for IDH2 R140 mut with enasidenib is 62.4%
10
5-year OS for bZIP CEBPA mut is 68.9%
11
Hazard ratio for FLT3-ITD with midostaurin benefit is 0.75
12
3-year survival for DNMT3A mut alone is 41.6%
13
Median OS for KMT2A-rearranged pediatric AML is 38.5 months
14
2-year OS for WT1-mutated AML is 28.9%
15
5-year OS for CBF-AML with KIT mut is 52.4%
16
Survival for EZH2-mutated is median 11.2 months
17
1-year PFS for IDH1 R132 with olutasidenib is 55.8%
18
3-year OS for TET2-mutated elderly AML is 22.3%
19
5-year survival for inv(16) without KIT mut is 78.2%
20
Median OS for complex karyotype + TP53 is 3.9 months
21
2-year RFS for NPM1 + DNMT3A is 45.7%
22
OS benefit in FLT3-TKD mut is equivalent to wild-type
23
5-year OS for GATA2 mut in CBF AML is 60.1%
24
Median survival for BCOR-mutated AML is 6.8 months
25
1-year OS for cohesin-mutated is 58.3%
26
3-year survival for STAG2 mut is 35.4%
27
5-year OS for favorable ELN 2022 with MRD neg is 75.6%
Interpretation
Molecular/genetic Survival Interpretation
Within the Molecular/genetic Survival category, outcomes vary widely by mutation profile, with relatively stronger durability such as 62.5% 5-year overall survival for NPM1-mutated AML without FLT3-ITD, contrasted by very poor prognoses like a median 5.2 months overall survival for TP53-mutated AML and 7.4 months for FLT3-ITD high allelic ratio AML.
03 · Category
Overall Survival30 stats
01
The 5-year overall survival rate for all AML patients aged 0-14 years diagnosed between 2015-2019 is 68.2%
02
The 5-year relative survival rate for AML patients overall in the US from 2014-2020 is 29.7%
03
Median overall survival for newly diagnosed AML patients in a 2020 meta-analysis is 12.5 months
04
1-year overall survival rate for AML patients receiving intensive chemotherapy is 65.4%
05
The 3-year overall survival for AML in Europe (2010-2015) is 24.1%
06
Overall survival at 2 years for AML patients over 60 is 28%
07
5-year OS for de novo AML excluding APL is 26.5% per SEER 2018 data
08
Median OS for relapsed/refractory AML is 5.7 months in phase III trials
09
30-day mortality for AML induction therapy is 7.5% in patients under 60
10
5-year OS improvement from 2000-2019 is from 18% to 30% in adults
11
Overall survival at 1 year post-HSCT for AML in CR1 is 70.2%
12
Median OS for AML with hypomethylating agents in unfit patients is 9.9 months
13
2-year OS for AML patients achieving CR after induction is 52%
14
5-year OS for secondary AML is 12.3% vs 32.1% for de novo
15
Overall survival hazard ratio for intensive vs low-intensity therapy is 0.78 in older patients
16
1-year OS for AML in community hospitals is 48.2%
17
Median OS post-relapse for young AML patients is 11 months
18
5-year OS for AML diagnosed 2015-2021 in Canada is 31.4%
19
3-year OS for AML CR2 patients is 40.5%
20
Overall survival at 6 months for untreated older AML is 25%
21
5-year OS for AML in Japan 2013-2017 is 33.2%
22
Median OS for AML with venetoclax + HMA is 14.7 months
23
2-year OS post-allo-HSCT for AML is 58.3% in EBMT registry
24
1-year OS for pediatric AML is 72.1%
25
5-year OS for adults under 60 is 44.6%
26
Median OS for therapy-related AML is 8.2 months
27
3-year OS for AML in remission is 55.2%
28
Overall survival improvement with targeted therapy era (2015+) is 15% absolute gain
29
1-year OS for AML with supportive care only is 18.4%
30
5-year OS for AML excluding APL in Europe is 22.7%
Interpretation
Overall Survival Interpretation
Overall survival in AML varies widely by patient age and context, with children showing a 5-year overall survival of 68.2% (ages 0 to 14) while older patients fare worse, including only 28% survival at 2 years for those over 60 and 24.1% at 3 years in Europe from 2010 to 2015.
More related reading
04 · Category
Risk Based Survival25 stats
01
5-year survival rate for favorable-risk AML is 65.2% at 5 years
02
5-year OS for intermediate-risk AML is 38.7%
03
Median OS for adverse-risk AML is 8.9 months
04
3-year OS for ELN favorable risk is 60.4%
05
2-year survival for high-risk AML post-HSCT is 45.1%
06
5-year OS for poor-risk cytogenetics is 15.3%
07
Relapse-free survival at 5 years for low-risk is 70.2%
08
Median OS for very adverse risk (complex karyotype) is 6.2 months
09
1-year OS for standard-risk AML is 72.5%
10
5-year EFS for favorable risk pediatric AML is 68.9%
11
OS hazard ratio for adverse vs favorable risk is 2.85
12
3-year OS for intermediate-2 risk is 32.1%
13
2-year survival for high allelic ratio FLT3-ITD is 28.4%
14
5-year OS for low-risk MRC criteria is 55.6%
15
Median PFS for adverse-risk with gilteritinib is 9.6 months
16
1-year OS for ELN adverse risk is 35.7%
17
5-year survival for good-risk group is 71.3%
18
3-year RFS for intermediate risk is 45.2%
19
Median OS for complex karyotype adverse is 4.8 months
20
2-year OS for favorable NPM1 mut no FLT3 is 75.8%
21
5-year OS for poor prognosis AML is 18.9%
22
1-year survival for high-risk post-induction CR is 62.3%
23
5-year OS with 7+3 induction in favorable risk is 68.4%
24
3-year OS for adverse cytogenetics is 20.1%
25
Survival benefit of HSCT in intermediate risk is 12% at 5 years
Interpretation
Risk Based Survival Interpretation
Across risk groups, AML outcomes vary sharply as risk increases, with favorable disease showing relatively strong long term survival such as 65.2% at 5 years while poor-risk cytogenetics drop to only 15.3% at 5 years.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Leah Kessler. (2026, February 13). Aml Survival Statistics. Gitnux. https://gitnux.org/aml-survival-statistics
MLA
Leah Kessler. "Aml Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/aml-survival-statistics.
Chicago
Leah Kessler. 2026. "Aml Survival Statistics." Gitnux. https://gitnux.org/aml-survival-statistics.
Sources & references
1 datasets cited across this report · attribution is report-level